Age Related Molecular Degeneration Market is likely to propel to US$ 22.19 Million by 2033 | Says Future Market Insights

The global age-related molecular degeneration market is currently valued at US$ 11.28 Million in 2023 and is anticipated to expand at a CAGR of 7%. Owing to the technological advances in healthcare the market is likely to propel to US$ 22.19 Million by 2033.

The increasing prevalence of AMD and a strong product pipeline are anticipated to be the major drivers for the growth of age-related molecular degeneration market. According to the WHO, around 196 million people were affected by age-related macular degeneration globally in 2020, including over 10.4 million moderate-to-severe vision impairment cases.

Globally, advanced age-related macular degeneration is the primary factor in irreversible blindness and visual impairment. As a result, the market for age-related macular degeneration is anticipated to experience significant growth over the forecast period.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-16152

Most severe eye conditions are rising globally, and vision loss is becoming a significant public health issue and increase in the prevalence of the retinal disorder in many developed and developing nations drive market growth. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.9% over the forecast period.

North America dominates the age-related molecular denegation market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region.

The significant R&D investments in Europe abode well for market growth. Growing awareness of macular degeneration in Asia-Pacific and the presence of key market players, and the rising elderly population in Japan all point to significant growth in the Japanese market for age-related molecular degeneration.

Key Takeaways from the Market Study

As of 2023, the age related molecular degeneration market was valued at US$ 11.28 Million
From 2023 to 2033, the age related molecular degeneration industry is poised to grow at an 7% CAGR
By 2033, the age related molecular degeneration market is slated to reach a valuation of US$ 22.19 Million
By distribution Channel, the hospital pharmacy segment accounted for the largest share of 55% and is expected to continue this trend over the forecast period.
China is poised to yield a CAGR of 6.8% with respect to age related molecular degeneration in 2033

“Growing healthcare spending and increase in the prevalence of AMD, retinal disorders are expected to radically transform the age-related molecular degeneration market in the coming years,” comments an analyst at FMI.

For more Report Customization, connect with us at https://www.futuremarketinsights.com/customization-available/rep-gb-16152

Competitive Landscape

Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Biogen, Samsung Bioepis, Ophthotech Corporation are some of the key players in the age related molecular degeneration industry.

The manufacturers are involved in the production of age related molecular degeneration in a larger capacity. Research and innovation are also conducted to launch innovative product for age related molecular degeneration.

In July 2021 – Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.
In June 2022- Biogen Inc. and Samsung Bioepis Co., Ltd announced that BYOOVIZ a biosimilar referencing LUCENTIS® has been launched in the United States. Healthcare provider engagement, promotional activity, collaborations with professional societies and patient advocacy groups have commenced and BYOOVIZ will be commercially available on July 1, 2022, through major distributors across the U.S.

More Valuable Insights Available

FMI, in its new offering, presents an unbiased analysis of the age related molecular degeneration market, presenting historical demand data (2018-2022) and forecast statistics for the period of 2023-2033.

The study divulges essential insights on the age related molecular degeneration market by Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy) by Region – Global Forecast 2023-2033

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16152

FMIs Domain Knowledge in Healthcare 

Our Healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the industrial automation sector. Our expertise in recognizing the challenges and trends impacting the global chemical & material industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.

Key Segments Covered in the Age-Related Molecular Degeneration Market Industry Survey

Age Related Molecular Degeneration Market by Product Type:
• Eylea
• Lucentis
• Beovu
• Others

Age Related Molecular Degeneration Market by Disease Type:
• Dry AMD
• Wet AMD

Age Related Molecular Degeneration Market by Distribution Channel:
• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

Explore Other Reports Links From Healthcare Market:

Empty Capsules Market : The global sales of empty capsules are anticipated to reach US$ 2.3 Billion in 2023. The market is further expected to increase at 7.9% CAGR during the forecast period, totaling a valuation of US$ 4.9 Billion by 2033.

Dermal Fillers Market : Dermal Fillers Market is projected to exhibit 7.5% CAGR between 2023 and 2033. They are used to rejuvenate different facial areas associated with various functionalities. The rising demand for facelift or face line corrections in various emerging countries is enabling the market growth.

Connected Drug Delivery Devices Market: The global Connected Drug Delivery Devices Market size was estimated at US$ 330 Mn in 2021, and is expected to reach US$ 1.6 Bn by 2028, expanding at a stellar CAGR of 23.6%.

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs